About a month after receiving the booster shot, study participants who got the omicron subvariant BA.4/BA.5-focused vaccine had “similar neutralizing antibody titers as those receiving a fourth monovalent mRNA vaccine.” All variants and subvariants were tested.
The study evaluated Pfizer’s and Moderna’s tweaked boosters, which were authorized Sept. 1. In recent weeks, the vaccine-makers have reported positive results showing their shots are safe and effective.
The researchers, who are from New York’s Columbia University and Ann Arbor’s University of Michigan, concluded that follow-up studies are needed to determine whether “antibody responses will deviate in time, including the impact of a second bivalent booster.”
More bivalent boosters could be on the horizon. Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci, MD, said in early September that COVID-19 vaccine jabs could become as regular as flu shots — but that could mean a universal vaccine, which is still in development, or a new modified vaccine every year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
